Eosinophilic Esophagitis Clinical Trial
Official title:
Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders
Verified date | May 13, 2015 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Food allergies are characterized by abnormal immune system responses to certain foods, such
as peanuts, strawberries, and shellfish. Some individuals with these allergies have immediate
allergic reactions on contact with the food in question and need immediate treatment to
prevent severe complications. In contrast, eosinophil-associated gastrointestinal disorders
are related disorders in which white blood cells in the intestinal tract react to certain
foods, causing abdominal pain, nausea, and other digestion problems. Researchers are
interested in studying these conditions to better understand how the immune system responds
to food allergies.
Objectives:
- To examine how the immune system responds to food allergens.
- To examine how certain white blood cells contribute to disease in individuals with food
allergies and other inflammatory diseases.
Eligibility:
- Individuals between 18 and 65 years of age who have a history of (a) severe allergic
reaction to peanuts (and have peanut-specific antibodies), (b) allergy or inflammatory
disease, or (c) eosinophil-associated gastrointestinal disorder (with at least two
documented food allergies).
- Healthy volunteers between 18 and 65 years of age who have no known allergies or asthma.
Design:
- All participants will have a screening visit and a procedure visit. The procedure visit
will take place within 30 to 60 days of the screening visit, and will take 3 to 4 hours
depending on the procedure(s) done.
- Participants will be screened with a physical examination and medical history, and will
provide blood samples for testing. Participants with peanut or other allergies will have
additional tests to determine their levels of sensitivity to certain foods. Participants
with eosinophil-associated gastrointestinal disorder will provide stool samples for
testing.
- At the procedure visit, participants with peanut allergies and participants with other
allergies will provide blood samples and have leukapherisis to collect white blood cells
for examination.
- At the procedure visit, healthy volunteers and participants with eosinophil-associated
gastrointestinal disorder will provide blood samples and have leukapherisis to collect
white blood cells for examination. In addition, some but not all of these participants
will have a procedure called esophagogastroduodenoscopy (EGD), which will examine the
esophagus, stomach, and small intestine. Participants who are scheduled to have EGD will
be asked to fast for 6 hours before the procedure.
Status | Terminated |
Enrollment | 162 |
Est. completion date | May 13, 2015 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
- INCLUSION CRITERIA: Subjects must meet all of the inclusion criteria: All Subjects must: 1. Be willing to have samples collected and stored for future research. 2. Have a documented clinical history compatible with EGID, peanut allergy, or other allergic and inflammatory diseases or be healthy without known allergic conditions. In addition to the above inclusion criteria for all subjects, the subjects in the following groups must meet additional group-specific inclusion criteria. Subjects with EGID must: 1. Be greater than or equal to 18 years of age 2. Maintain a primary non-NIH physician for routine care 3. Have one of the types of EGID below: - Eosinophilic gastroenteritis: Have a clinical history of eosinophilic gastroenteritis -including gastrointestinal symptoms-, and histological evidence of stomach or duodenal eosinophilia with no other known etiology for the eosinophilia despite careful clinical evaluation. OR -Eosinophilic esophagitis: Have a diagnosis of eosinophilic esophagitis, including evidence of esophageal dysfunction with a peak count of greater than or equal to 25 eosinophils per high powered field, for which the biopsy was obtained while under proton pump inhibitor treatment. OR -Probable eosinophilic esophagitis: Have a likely diagnosis of eosinophilic esophagitis, based on evidence of esophageal dysfunction and a peak count of greater than or equal to 15 eosinophils per high powered field, but for which the biopsy was not obtained under proton pump inhibitors (per section 6.3). To confirm a diagnosis of EoE, these subjects may be treated with proton pump inhibitor therapy at recommended doses for gastroesophageal reflux disease for at least 84 weeks prior to EGD and biopsy. The decision to recommend diagnostic biopsy will be according to concensus guidelines [7] and current standards of care: based on the severity of symptoms, history of food impactions, and evidence of remodeling (strictures). Subjects with Peanut Allergy: 1. Be greater than or equal to 18 years of age and less than or equal to 65 years of age. 2. Have a history of immediate hypersensitivity to peanuts with involvement of at least one extracutaneous site, including wheezing, laryngeal edema, angioedema, vomiting, diarrhea, hypotension and circulatory collapse. 3. Have peanut specific IgE of greater than or equal to 5 kIU/L. Subjects with Other Allergic and Inflammatory Diseases: 1. Be greater than or equal to 18 years of age and less than or equal to 65 years of age. 2. These subjects must be diagnosed with an allergic or an inflammatory disease, including anaphylaxis, asthma, or hay fever. Diagnosis will be based on established criteria for each clinical entity. Healthy, Non-Atopic Subjects: 1. Be greater than or equal to 18 years of age and less than or equal to 65 years of age. 2. Have no history of allergies, asthma or food allergy 3. Have a negative ImmunoCAP fx5 in vitro food allergy screen for allergen specific IgE to egg white, milk, cod, wheat, peanut, and soy 4. Have a negative Phadiatop allergy screen EXCLUSION CRITERIA: Subjects with any of the following criteria will be excluded: 1. Any other condition that, in the investigator s opinion, places the subject at undue risk by participating in the study Subjects with Peanut Allergy with any of the following will be excluded: 1. Chronic upper GI symptoms that are consistent with EGID (dysphagia, nausea, vomiting, abdominal pain/cramps, early satiety) PROCEDURAL INCLUSIONS: Subjects with EoE and EG undergoing research EGD or lymphapheresis must: 1. Be greater than or equal to 18 years of age and less than or equal to 65 years of age. Subjects with EG undergoing EGD or lymphapheresis must have: 1. Histological evidence of stomach or duodenal eosinophilia with a peak count greater than or equal to 40 eosinophils per high powered field 2. Greater than two positive allergen skin tests or antigen specific IgE tests out of the following panel (peanut, wheat, soy, shrimp, egg white, milk, walnut, cod, corn) Subjects with either EG or EoE undergoing lymphapheresis must have: 1. An absolute eosinophil count of >750 eos/microL at least once in the last 2 years Subjects with EoE undergoing EGD must have: 1. Diagnosed EoE per section 5.1 with a previous biopsy showing greater than or equal to 25 eosinophils per high powered field, OR 2. Probable eosinophilic esophagitis per section 5.1 with a previous biopsy showing greater than or equal to 25 eosinophils per high powered field PROCEDURAL EXCLUSIONS: Subjects with any of following will not undergo EGD: 1. Uncontrolled asthma or Grade 3 or higher by the American Society of Anesthesiologist s (ASA) Physical Status Classification System. 2. History of adverse reaction to conscious sedation required for EGD. Subjects with any of following will not undergo EGD or lymphapheresis: 1. Hemoglobin <12 g/dL 2. Viral screens positive for HIV or hepatitis B or C 3. Pregnant or breast-feeding women Control Subjects (Healthy, Non-Atopic) Undergoing EGD with any of the following will be excluded: 1. History of reflux or use of acid suppression medication within the last 6 months. 2. Chronic gastrointestinal disease or immunological disease. 3. Clinically indicated EGD in the past 12 months. 4. Use of systemic corticosteroids in the past 6 months. EGID subjects who are pregnant or breast-feeding may be followed without research phlebotomy. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, Bonis P, Hassall E, Straumann A, Rothenberg ME; First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007 Oct;133(4):1342-63. Epub 2007 Aug 8. Review. — View Citation
Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006 Feb;117(2):391-7. — View Citation
Sicherer SH, Sampson HA. Food allergy: recent advances in pathophysiology and treatment. Annu Rev Med. 2009;60:261-77. doi: 10.1146/annurev.med.60.042407.205711. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quantitation of gut tissue IL-5+ and IL-5- Th2 cells in EGIDs and in healthy non-atopic subjects. | End of study | ||
Primary | Quantitation of gut tissue Th2 cells using alternative techniques (GATA3 immunohistochemistry, RT-PCR) in EGIDs and in healthy non-atopic subjects. | End of study | ||
Primary | Quantitation of gut tissue IFN-, IL- 17 and IL-10 producing cellpopulations in EGIDs and in healthy non-atopic subjects. | End of study | ||
Secondary | Characterization of gut homing food allergen specific T cells | End of study | ||
Secondary | Characterization of Pro-anaphylactic follicular helper Th2 cells in foodallergy | End of study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03382678 -
CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry
|
||
Completed |
NCT05083312 -
Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial
|
Phase 3 | |
Completed |
NCT04593251 -
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
|
Phase 1 | |
Completed |
NCT03633617 -
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
|
Phase 3 | |
Completed |
NCT04941742 -
The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis (Validation Phase)
|
||
Terminated |
NCT04543409 -
A Study of Benralizumab in Patients With Eosinophilic Esophagitis
|
Phase 3 | |
Terminated |
NCT02314455 -
Esophageal Absorption in EoE
|
N/A | |
Completed |
NCT01953575 -
Mucosal Impedance and Eosinophilic Esophagitis
|
N/A | |
Completed |
NCT01386112 -
Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04991935 -
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
|
Phase 3 | |
Not yet recruiting |
NCT05896891 -
San Raffaele EoE Biobank
|
||
Active, not recruiting |
NCT05482256 -
A Study of Detergents in the Pathogenesis of Eosinophilic Esophagitis
|
N/A | |
Recruiting |
NCT05485155 -
Zemaira Eosinophilic Esophagitis Pilot Study
|
Phase 2 | |
Recruiting |
NCT04149470 -
Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)
|
Phase 4 | |
Recruiting |
NCT04416217 -
Eosinophilic Esophagitis Steroid Safety Study
|
||
Completed |
NCT05084963 -
A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
|
Phase 2 | |
Completed |
NCT02579876 -
Milk Patch for Eosinophilic Esophagitis
|
Phase 2 | |
Recruiting |
NCT02331849 -
Esophageal Motility in Eosinophilic Esophagitis Evaluated by High Resolution Manometry.
|
N/A | |
Active, not recruiting |
NCT02202590 -
Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus
|
N/A | |
Active, not recruiting |
NCT05176249 -
Prospective Database for Eosinophilic Esophagitis (EoE) of Pediatric Population
|